SION Stock Analysis: Buy, Sell, or Hold?
SION - Sionna Therapeutics, Inc. Common Stock
$39.87
1.04 (2.68%)
▲
5d:
+10.75%
30d:
-4.5%
90d:
+9.44%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When SION Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: SION shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: SION shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: SION is currently trading at $39.87, which is considered slightly high relative to its 30-day fair value range of $35.18 to $41.23.
Technical Outlook: Technically, SION is showing sideways momentum. Immediate support is located at $32.33, while resistance sits at $42.31.
Market Sentiment: SION has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $51.60 (+29.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SION is showing sideways momentum. Immediate support is located at $32.33, while resistance sits at $42.31.
Market Sentiment: SION has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $51.60 (+29.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$35.18 -
$41.23
Company Quality Score
55/100
(HOLD)
Options IV Signal
7th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- BULLISH: Options cheap (IV 7th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 29.4% below Wall St target ($51.60)
Trading Range Analysis
30-Day Trading Range
$35.18 -
$41.23
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$5.68
(14.2%)
Support & Resistance Levels
Support Level
$32.33
Resistance Level
$42.31
Current Trend
Sideways
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.23
Wall Street Target
$51.60
(+29.4%)
Share & Embed Analysis
Last updated: June 24, 2026 8:56 AM ET
Data refreshes hourly during market hours. Next update: 9:56 AM
Data refreshes hourly during market hours. Next update: 9:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SION showing a specific setup today?
Insider Activity (6 Months)
0
Buys
15
Sells
Net
INSIDERS SELLING
Recent Transactions
Peter A Thompson
SELL
2948 shares
2026-04-18
Orbimed Advisors Llc
SELL
2948 shares
2026-04-18
Orbimed Advisors Llc
SELL
52397 shares
2026-04-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 60 BUY |
